Key Details
Price
$80.31Annual ROE
225.83%Beta
0.97Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 3, 2011Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
The FDA has approved a priority review for INSM's New Drug Application (NDA) for brensocatib, which is intended for patients with non-cystic fibrosis bronchiectasis. A decision on this application is expected by August 12, 2025.
BRIDGEWATER, N.J., Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on putting people first, aims to provide top-quality treatments for patients with serious illnesses. Today, they announced that they have given inducement awards to 66 new staff members.
Brensocatib could become the first and only treatment for bronchiectasis if it gets approved. Insmed Incorporated, a biopharmaceutical company focused on improving patients' lives, announced that the FDA has accepted their New Drug Application for brensocatib, aimed at patients with non-cystic fibrosis bronchiectasis. This drug would also be the first DPP1 inhibitor available.
We have put together a list of the 10 Best Russell 2000 Stocks to Invest in Based on Analyst Recommendations. In this article, we will examine how Insmed Incorporated (NASDAQ:INSM) compares to other top Russell 2000 stocks recommended by analysts. The Russell 2000 Index is a popular benchmark that...
Insmed Incorporated has reported that its ARIKAYCE® product has achieved global revenues of about $363.7 million for 2024, exceeding expectations. For 2025, the company anticipates revenues for ARIKAYCE to be between $405 million and $425 million, indicating continued growth. Additionally, they have submitted a New Drug Application for Brensocatib and completed enrollment for a Phase 2 study of TPIP, with results expected in mid-2025.
BRIDGEWATER, N.J., Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on putting people first, aims to provide top-quality treatments for patients with serious illnesses. Today, they announced that they have given inducement awards to 19 new staff members.
BRIDGEWATER, N.J., Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on prioritizing patients, has announced that its management team will speak at the 43rd Annual J.P.
We have just put together a list of the 12 Best Multibagger Stocks to Invest in at the moment. In this article, we will examine how Insmed Incorporated (NASDAQ:INSM) compares to the other multibagger stocks. The US stock market has been rising in 2024, helping the S&P 500 reach new record levels.
BRIDGEWATER, N.J., Dec. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on putting people first, has announced that it has given inducement awards to 30 new employees. The company aims to provide top-quality therapies to improve the lives of patients with serious illnesses.
Insmed Incorporated's ARIKAYCE, which is approved for MAC lung disease, saw significant revenue growth in the third quarter of 2024 and may receive expanded FDA approval, increasing its market potential. The company plans to file a New Drug Application for Brensocatib for bronchiectasis in the fourth quarter of 2024, with a possible U.S. launch by mid-2025. Additionally, results from a phase 2b study using TPIP for treating patients with PAH are anticipated in the second half of 2025.
FAQ
- What is the ticker symbol for Insmed Incorporated?
- Does Insmed Incorporated pay dividends?
- What sector is Insmed Incorporated in?
- What industry is Insmed Incorporated in?
- What country is Insmed Incorporated based in?
- When did Insmed Incorporated go public?
- Is Insmed Incorporated in the S&P 500?
- Is Insmed Incorporated in the NASDAQ 100?
- Is Insmed Incorporated in the Dow Jones?
- When was Insmed Incorporated's last earnings report?
- When does Insmed Incorporated report earnings?
- Should I buy Insmed Incorporated stock now?